![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png){kind=small}
$84,000 cure for hepatitis C
Интересная заметка о том, какую ракцию отторжения вызывает у определенной (понятно какой) части общества тот факт, что кто-то может брать по $1,000 за таблетку. (Заодно становится понятно почему так выросли цены на биотехнические акции.)
By any objective metric, Sovaldi is a good value. The drug costs less on an absolute basis than (предыдущее стандартное лекарство) Incivek (~$100,000 per year), which is reimbursed without question, and is an even better deal if one applies a “cost per cure” methodology (A recent Mt. Sinai study shows a $189,000 cost per cure for Incivek-containing regimens.) Moreover, remember that the government pays nowhere near list price; Medicaid receives a mandatory 23.1% discount on branded drug prices (Sovaldi is covered by privately-administered Medicare Part D plans for patients over 65 years old).
So why all the fuss?...
It doesn't help that Gilead is offering Sovaldi in Egypt at a 99 percent discount to U.S. prices, or about $900 for a full course of treatment.
By any objective metric, Sovaldi is a good value. The drug costs less on an absolute basis than (предыдущее стандартное лекарство) Incivek (~$100,000 per year), which is reimbursed without question, and is an even better deal if one applies a “cost per cure” methodology (A recent Mt. Sinai study shows a $189,000 cost per cure for Incivek-containing regimens.) Moreover, remember that the government pays nowhere near list price; Medicaid receives a mandatory 23.1% discount on branded drug prices (Sovaldi is covered by privately-administered Medicare Part D plans for patients over 65 years old).
So why all the fuss?...
It doesn't help that Gilead is offering Sovaldi in Egypt at a 99 percent discount to U.S. prices, or about $900 for a full course of treatment.
no subject
no subject
самая что ни на есть соц.система, " от каждого по способности",
"Gilead wants to tier its pricing based on a country's per-capita income"